Esperion Therapeutics Inc (ESPR) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Esperion Therapeutics Inc   (NASDAQ: ESPR)


Esperion Therapeutics Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Esperion Therapeutics Inc's ROI in the first quarter of 2026?
Esperion Therapeutics Inc recorded a cumulative net loss of $-7 million during 12 months ending in the first quarter of 2026, resulting in a negative return on investment (ROI) of -7.8%.

Within the Healthcare sector 261 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from 2545 to 2943.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM -20.04 % -30.5 % 104.83 % - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 162 165 5 48 53
Return On Investment (TTM) -7.8 % -33.43 % -207.59 % -119.85 % -128.79 %
ESPR's Overall Ranking # 2943 # 2545 # 3914 # 3003 # 3952
Seq. Investment Change TTM 40.2 % 33.09 % -41.26 % -27.04 % 21.85 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -7 -23 -106 -104 -153

ESPR Company Profile >> Back to ESPR Roi Comparisons >> See Annual ESPR Return On Investment



Return On Investment ESPR's Ranking
Within: No.
Industry # 90
Sector # 262
Overall # 2943

Return On Investment Statistics
High Average Low
-7.73 %
-78.8 %
-201.06 %
(Mar 31 2026)   (Sep 30 2025)



  News about Esperion Therapeutics Inc Return on Investment ROI

Esperion Therapeutics: Navigating a New Financial Horizon Amid Market Uncertainty

December 18, 2024

As the biotechnology sector continues to navigate the turbulent seas of market volatility, few companies exemplify this challenge like Esperion Therapeutics Inc. (NASDAQ: ESPR). In its latest financial maneuvers, the company has caught the attention of investors and analysts alike with its proactive steps to strengthen its balance sheet. Esperion, focused on developing innovative therapies for cardiovascular diseases, is determined to maintain its footing amid industry fluctuations and investor skepticism.On December 15, 2024, Esperion Therapeutics announced the successful closure of a significant refinancing transaction that may reshape its fiscal landscape. The company secured a $150 million senior secured term loan credit facility along with a new $100 million convertible note. This strategic move aims to repay a substantial portion of the existing $265 million convertible debt, enhancing the company s liquidity and positioning it for future growth.





Financial Statements
Esperion Therapeutics Inc's I. Quarter Investments $ 162 Millions ESPR's Balance sheet
Esperion Therapeutics Inc's I. Quarter Income $ -25 Millions Quarterly ESPR's Income Statement
ESPR's Income by Division See ESPR's Income by Division


ESPR Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 165 98 -193 -64 308
Y / Y Investment Growth 69.16 % - - - 18.92 %
Net Income in Millions -23 -52 -209 -234 -269
Y / Y Net Income Growth - - - - -
Annual Return On Investment -13.74 % -53.02 % - - -87.31 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ESPR's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ESPR's Competitors
Subscribers only: Roi for Esperion Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ESPR's Customers

Other Ratios
ESPR's Roa ESPR's Inventory Turnover Ratio ESPR's Growth Rates ESPR's Dividend Statistics
ESPR's Profitability Ratios ESPR's Asset Turnover Ratio ESPR's Dividend Growth
ESPR's Roe ESPR's Valuation Ratios ESPR's Financial Strength Ratios ESPR's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:26:14+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.